2025
Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis
Oldham J, Neely M, Wojdyla D, Gulati M, Li P, Patel D, Palmer S, Todd J, Investigators I. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. CHEST Journal 2025 PMID: 40020995, DOI: 10.1016/j.chest.2025.02.018.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisLung transplantationLung function declinePulmonary fibrosisAssociated with 1.8-foldProgressive fibrosing interstitial lung diseaseMedian follow-up timeFibrosing interstitial lung diseaseFollow-up timeInterstitial lung diseaseCox proportional hazards modelsRisk of deathFunctional declineRisk of mortalityProportional hazards modelAntifibrotic treatmentThreshold of declineAssociated with lung function declineOutcomes RegistryLung diseaseEnrolling centersDLCOSmoking statusDiffusing capacityLung functionEpigenetic age acceleration in idiopathic pulmonary fibrosis revealed by DNA methylation clocks
Kurbanov D, Ahangari F, Adams T, De Man R, Tang J, Carlon M, Abu Hussein N, Cortesi E, Zapata M, De Sadelaar L, Wuyts W, Vanaudenaerde B, Kaminski N, McDonough J. Epigenetic age acceleration in idiopathic pulmonary fibrosis revealed by DNA methylation clocks. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2025, 328: l456-l462. PMID: 39970931, DOI: 10.1152/ajplung.00171.2024.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisIdiopathic pulmonary fibrosis tissuePulmonary fibrosisLung tissueEpigenetic clocksPotential of DNA methylationDNA methylation levelsDebilitating lung diseaseIllumina MethylationEPIC arrayHuman lung tissueEpigenetic ageDNA methylation clocksBiological ageAffected lung tissueIPF casesClinical prognosisMethylation patternsDNA methylationLung diseaseHealthy controlsAcceleration of biological agingMethylation levelsMethylationEPIC arrayAge accelerationClinical assessmentInvestigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis
Spagnolo P, Tonelli R, Mura M, Reisman W, Sotiropoulou V, Tzouvelekis A. Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis. Expert Opinion On Investigational Drugs 2025, 34: 61-80. PMID: 39916340, DOI: 10.1080/13543784.2025.2462592.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisGene therapyPulmonary fibrosisAssociated with tolerability issuesProgressive fibrosing interstitial lung diseaseEfficacy of gene therapyApplication of gene therapyTreatment of idiopathic pulmonary fibrosisLong-term clinical dataFibrosing interstitial lung diseaseFirst-line therapyImproved vector designInterstitial lung diseaseMitigate off-target effectsTolerated treatmentDismal prognosisClinical dataLung diseaseClinical studiesAssociated with poor qualityProfibrotic pathwaysTarget cellsTherapyFibrosisOff-target effectsCollagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis.
Ahmad A, Ghim M, Kukreja G, Neishabouri A, Zhang Z, Li J, Salarian M, Toczek J, Gona K, Hedayatyanfard K, Morrison T, Zhang J, Huang Y, Liu C, Yu S, Sadeghi M. Collagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis. Journal Of Nuclear Medicine 2025, 66: 425-433. PMID: 39915119, PMCID: PMC11876730, DOI: 10.2967/jnumed.124.268832.Peer-Reviewed Original ResearchConceptsPulmonary fibrosisTracer uptakeLung uptakeMurine model of pulmonary fibrosisModel of pulmonary fibrosisMice 3 wkEffect of antifibrotic therapyCollagen turnoverInterstitial lung diseaseClinical diagnostic methodsSPECT/CT imagingHybrid tracersLung histologyAntifibrotic therapyControl miceDisease activityMurine modelLung diseaseMice 8Tissue fibrosisPatient managementLiver uptakeSPECT/CTFibrosisSPECT imagesDiagnosis, screening, and follow-up of patients with familial interstitial lung disease: Results from an international survey
Moen E, Prior T, Kreuter M, Wuyts W, Molina-Molina M, Wijsenbeek M, Morais A, Tzouvelekis A, Ryerson C, Caro F, Buendia-Roldan I, Magnusson J, Lee J, Morisett J, Oldham J, Troy L, Funke-Chambour M, Alberti M, Borie R, Walsh S, Rajan S, Kondoh Y, Khor Y, Bendstrup E. Diagnosis, screening, and follow-up of patients with familial interstitial lung disease: Results from an international survey. BMC Pulmonary Medicine 2025, 25: 59. PMID: 39901224, PMCID: PMC11792556, DOI: 10.1186/s12890-025-03532-0.Peer-Reviewed Original ResearchConceptsGenetic testing methodsMultidisciplinary teamGenetic testingFamily historyInterstitial lung diseaseHistory of interstitial lung diseaseRecommended genetic testingScreening of first-degree relativesFamilial interstitial lung diseaseEvidence-based guidelinesGenetic screening of relativesScreening of relativesFirst-degree relativesCharacteristics of respondentsInternational surveyPathogenic genetic variantsScreening toolLung transplantationInsufficient evidenceLung diseaseConsensus statementGenetic variantsFollow-up of patientsStandard programRespondentsThe fungal microbiota modulate neonatal oxygen-induced lung injury
Martin I, Silverberg M, Abdelgawad A, Tanaka K, Halloran B, Nicola T, Myers E, Desai J, White C, Karabayir I, Akbilgic O, Tipton L, Gentle S, Ambalavanan N, Peters B, Vu L, Jain V, Lal C, Cormier S, Pierre J, Jilling T, Talati A, Willis K. The fungal microbiota modulate neonatal oxygen-induced lung injury. Microbiome 2025, 13: 24. PMID: 39871397, PMCID: PMC11773857, DOI: 10.1186/s40168-025-02032-x.Peer-Reviewed Original ResearchConceptsBronchopulmonary dysplasiaLung injury severityLung injuryDevelopment of bronchopulmonary dysplasiaSeverity of lung injuryAugmented lung injuryMorbidities of prematurityVery preterm infantsOxygen-induced lung injuryChronic lung diseaseIntestinal microbiomeMicrobiome of infantsPotential therapeutic strategyPreterm infantsNeonatal microbiomePremature infantsPremature neonatesInjury severityMurine modelNeonatal healthLung diseaseMouse modelTherapeutic strategiesLoss of function approachesFungal communities
2024
Evaluating fatigue and excessive daytime sleepiness: a comparative analysis of prevalence and correlating factors in interstitial lung disease patients and healthy controls
Ouyang X, Shen Q, Zhou S, Zhou P, Song M, Guo T, Guo W, Zhang Y, Peng H. Evaluating fatigue and excessive daytime sleepiness: a comparative analysis of prevalence and correlating factors in interstitial lung disease patients and healthy controls. Annals Of Medicine 2024, 56: 2398729. PMID: 39624966, PMCID: PMC11616753, DOI: 10.1080/07853890.2024.2398729.Peer-Reviewed Original ResearchInterstitial lung disease patientsInterstitial lung diseaseDiminished exercise capacityExcessive daytime sleepinessHealthy volunteersExercise capacityDaytime sleepinessEpworth Sleepiness Scale scoreQuality of lifePulmonary diffusion functionSleepiness Scale scoreFactors associated with excessive daytime sleepinessSecond Xiangya HospitalLogistic regressionLung disease patientsMultivariate logistic regressionDecreased quality of lifeCentral South UniversityCross-sectional studyPrevalence of fatigueChest painConsecutive patientsClinical characteristicsNon-ED patientsLung diseasePrecision-Cut Lung Slices: Emerging Tools for Preclinical and Translational Lung Research: An Official American Thoracic Society Workshop Report
Lehmann M, Krishnan R, Sucre J, Kulkarni H, Pineda R, Anderson C, Banovich N, Behrsing H, Dean C, Haak A, Gosens R, Kaminski N, Zagorska A, Koziol-White C, Metcalf J, Kim Y, Loebel C, Neptune E, Noel A, Raghu G, Sewald K, Sharma A, Suki B, Sperling A, Tatler A, Turner S, Rosas I, van Ry P, Wille T, Randell S, Pryhuber G, Rojas M, Bourke J, Königshoff M. Precision-Cut Lung Slices: Emerging Tools for Preclinical and Translational Lung Research: An Official American Thoracic Society Workshop Report. American Journal Of Respiratory Cell And Molecular Biology 2024, 72: 16-31. PMID: 39499861, PMCID: PMC11707673, DOI: 10.1165/rcmb.2024-0479st.Peer-Reviewed Original ResearchPrecision cut lung slicesClinically relevant readoutsDevelopment of tailored therapiesChronic lung diseaseLung disease patientsClinical metadataPatient endotypesPreclinical platformTailored therapyLung diseasePulmonary medicineEffective treatmentLung slicesDisease patientsRelevant readoutsMultiomics analysisPatientsLung researchEndotypesTherapyCorrigendum to “Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease” [Autoimmunity Reviews - Volume 23, Issue 6, June 2024, 103582]
Guiot J, Miedema J, Cordeiro A, De Vries-Bouwstra J, Dimitroulas T, Søndergaard K, Tzouvelekis A, Smith V. Corrigendum to “Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease” [Autoimmunity Reviews - Volume 23, Issue 6, June 2024, 103582]. Autoimmunity Reviews 2024, 23: 103641. PMID: 39369613, DOI: 10.1016/j.autrev.2024.103641.Peer-Reviewed Original Research129Xe magnetic resonance imaging for monitoring lung function and microstructure in patients on treatment for progressive fibrosing interstitial lung disease
Kern A, Voskrebenzev A, Klimeš F, Pink I, Schupp J, Seeliger B, Konietzke M, Peter D, Risse F, Welte T, Wacker F, Hohlfeld J, Shin H, Prasse A, Vogel-Claussen J. 129Xe magnetic resonance imaging for monitoring lung function and microstructure in patients on treatment for progressive fibrosing interstitial lung disease. 2024, oa5465. DOI: 10.1183/13993003.congress-2024.oa5465.Peer-Reviewed Original ResearchToll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.
Trujillo G, Regueiro-Ren A, Liu C, Hu B, Sun Y, Ahangari F, Fiorini V, Ishikawa G, Al Jumaily K, Khoury J, McGovern J, Lee C, Peng X, Pivarnik T, Sun H, Walia A, Woo S, Yu S, Antin-Ozerkis D, Sauler M, Kaminski N, Herzog E, Ryu C. Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2024, 211: 91-102. PMID: 39189851, PMCID: PMC11755360, DOI: 10.1164/rccm.202401-0065oc.Peer-Reviewed Original ResearchToll-like receptor 9Model of pulmonary fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisFibroproliferative responseLung diseaseIdiopathic pulmonary fibrosis cohortsExpression of toll-like receptor 9Toll-like receptor 9 activationTransplant-free survivalExpression of MCP-1Cohort of patientsSlow clinical progressionFibrotic lung diseaseAccelerated disease courseFatal lung diseaseIP-10Pharmacodynamic endpointsPreclinical modelsDisease courseClinical progressionPlasma mtDNAMCP-1Receptor 9Mouse modelPhylogeographic Analysis of Mycobacterium kansasii Isolates from Patients with M. kansasii Lung Disease in Industrialized City, Taiwan - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
Cudahy P, Liu P, Warren J, Sobkowiak B, Yang C, Ioerger T, Wu C, Lu P, Wang J, Chang H, Huang H, Cohen T, Lin H. Phylogeographic Analysis of Mycobacterium kansasii Isolates from Patients with M. kansasii Lung Disease in Industrialized City, Taiwan - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1562-1570. PMID: 39043390, PMCID: PMC11286038, DOI: 10.3201/eid3008.240021.Peer-Reviewed Original ResearchConceptsM. kansasii lung diseaseM. kansasii pulmonary diseasePulmonary diseaseM. kansasii isolatesSputum mycobacterial cultureWhole-genome sequencingEvaluate risk factorsPhylogeographic analysisAge of participantsGenetic relatednessEnvironmental acquisitionLung diseaseMycobacterial cultureOdds ratioRisk factorsM. kansasiiPatientsDiseasePlantsEnvironmental transmissionIsolatesPark plantingsCDCRiskInterstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations
Sampsonas F, Bosgana P, Bravou V, Tzouvelekis A, Dimitrakopoulos F, Kokkotou E. Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations. Genes 2024, 15: 934. PMID: 39062713, PMCID: PMC11276289, DOI: 10.3390/genes15070934.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseLung cancerLung diseaseDriver mutationsImproved survivalTreatment optionsChronic inflammationPathogenetic pathwaysNon-small cell lung cancerConcurrent interstitial lung diseaseCell lung cancerSites of chronic inflammationAnti-fibrotic medicationsCurrent treatment optionsIdiopathic pulmonary fibrosisDiseases associated with chronic inflammationIncidence of lung cancerPersonalized medicine approachPrompt diagnosisClinical entityNon-smallPulmonary fibrosisNSCLCSurvival ratePatients2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care & Research 2024, 76: 1070-1082. PMID: 38973729, DOI: 10.1002/acr.25347.Peer-Reviewed Original ResearchSystemic autoimmune rheumatic diseasesInterstitial lung diseasePulmonary function testsAutoimmune rheumatic diseasesMonitoring of interstitial lung diseaseChest radiographyHigh-resolution computed tomography of the chestInterstitial lung disease risk factorsLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeDevelopment of interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansHigh-resolution computed tomographyMonitoring interstitial lung diseasesSurgical lung biopsyIdiopathic inflammatory myopathiesConnective tissue diseaseClinical practice guidelinesWalk test distanceGrading of RecommendationsEvidence-based recommendationsLung biopsy2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & Rheumatology 2024, 76: 1201-1213. PMID: 38973714, DOI: 10.1002/art.42860.Peer-Reviewed Original ResearchSystemic autoimmune rheumatic diseasesInterstitial lung diseasePulmonary function testsAutoimmune rheumatic diseasesMonitoring of interstitial lung diseaseChest radiographyHigh-resolution computed tomography of the chestInterstitial lung disease risk factorsLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeDevelopment of interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansHigh-resolution computed tomographyMonitoring interstitial lung diseasesSurgical lung biopsyIdiopathic inflammatory myopathiesConnective tissue diseaseClinical practice guidelinesWalk test distanceGrading of RecommendationsEvidence-based recommendationsLung biopsy2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & Rheumatology 2024, 76: 1182-1200. PMID: 38978310, DOI: 10.1002/art.42861.Peer-Reviewed Original ResearchTreatment of interstitial lung diseaseSystemic autoimmune rheumatic diseasesInterstitial lung diseaseAutoimmune rheumatic diseasesLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeProgressive interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansClinical practice guidelinesGrading of RecommendationsEvidence-based recommendationsClinically relevant populationOutcome questionsPractice guidelinesSystematic literature reviewDiseasePhysiciansTreatmentGlucocorticoidTherapyRelevant populationRecommendations2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care & Research 2024, 76: 1051-1069. PMID: 38973731, DOI: 10.1002/acr.25348.Peer-Reviewed Original ResearchTreatment of interstitial lung diseaseSystemic autoimmune rheumatic diseasesInterstitial lung diseaseAutoimmune rheumatic diseasesLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeProgressive interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansClinical practice guidelinesGrading of RecommendationsEvidence-based recommendationsClinically relevant populationOutcome questionsPractice guidelinesSystematic literature reviewDiseasePhysiciansTreatmentGlucocorticoidTherapyRelevant populationRecommendationsA Brief Report of Lung Cancer Screening Utilization Before, During, and in the Later Stages of the COVID-19 Pandemic in the United States
Poghosyan H, Sarkar S, Richman I, Pietrzak R, Carter-Bawa L, Cooley M. A Brief Report of Lung Cancer Screening Utilization Before, During, and in the Later Stages of the COVID-19 Pandemic in the United States. JTO Clinical And Research Reports 2024, 5: 100705. PMID: 39282662, PMCID: PMC11402037, DOI: 10.1016/j.jtocrr.2024.100705.Peer-Reviewed Original ResearchLung cancer screeningLung cancer screening utilizationScreening utilizationBehavioral Risk Factor Surveillance SystemRates of lung cancer screeningRisk Factor Surveillance SystemScreening-eligible individualsCancer screening utilizationLung cancer burdenPopulation-based dataMultivariate logistic regressionCancer screeningCancer burdenImpact healthcareNational ratesIncreased oddsLogistic regressionNationwide effortSurveillance systemCOVID-19COVID-19 pandemicLung diseaseBrief reportNo sex differencesUnited StatesDisorders with Ophthalmic and Thoracic Involvement.
Gosangi B, Lang P, Johnson M, Zukerman R, Tu L, Traube L, Bader A, Rubinowitz A. Disorders with Ophthalmic and Thoracic Involvement. RadioGraphics 2024, 44: e230132. PMID: 38870047, DOI: 10.1148/rg.230132.Peer-Reviewed Original ResearchConceptsClinical manifestationsExamination of family membersEhlers-Danlos syndromeAffecting patient outcomesAcute sarcoidosisOphthalmologic examinationThoracic symptomsDry eyeThoracic involvementOphthalmological symptomsOphthalmologic manifestationsEye symptomsMarfan syndromeSjogren's syndromeImaging findingsRadiological studiesLung diseasePatient outcomesEhlers-DanlosFamily membersMultimodal imagingSystem conditionsSyndromeThoracicSarcoidosisConventional and Contrast-enhanced US of the Lung: From Performance to Diagnosis.
Jiménez-Serrano S, Páez-Carpio A, Doménech-Ximenos B, Cornellas L, Sánchez M, Revzin M, Vollmer I. Conventional and Contrast-enhanced US of the Lung: From Performance to Diagnosis. RadioGraphics 2024, 44: e230171. PMID: 38935548, DOI: 10.1148/rg.230171.Peer-Reviewed Original ResearchConceptsPeripheral lung diseaseContrast-enhanced USDiagnosis of peripheral lung diseasePercutaneous biopsyLung USEnhancement patternLung diseaseImage-guided percutaneous biopsyAccurate differential diagnosisDiagnostic chest imagingLung biopsySubpleural lesionsConventional USDifferential diagnosisPathological findingsPulmonary physiologyChest imagingArterial supplyBiopsyLungDiagnostic testsDiagnosisSoft tissueDiseaseImaging time
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply